- Email: [email protected]
Recombinant hepatitis B virus gene expression in Vero cell culture
Gene fragment of varicella zoster virus used for producing a polypeptide for use as a vaccine against VZV disease and chicken pox
Merck USA Eur. 210 931; 4 January 1987 A 2.6 kb fragment of varicella zoster virus (VZV) D N A having a specified D N A sequence is new. The polypeptide encoded by the D N A and having a specified amino acid sequence is also new. The polypeptide can be used as a vaccine to protect against VZV disease. The antigens can also be used diagnostically to measure VZV titres. Plasmids from a VZV genomic library are used to hybrid-select R N A from VZV-infected cells. In vitro translational products are immunoprecipitated by guinea pig antibodies raised to gB glycoprotein purified by monoclonal antibody affinity chromatography. It is found that a 100kDa polypeptide is immunoprecipitated from m R N A selected by the HindllI-D fragment. DNA sequence analysis of this region of the VZV genome reveals a 2.6 kb open reading frame (ORF) which could encode a 100 kDa protein with a glycoprotein-like structure (hydrophobic leader, hydrophobic anchor, 9-N-glycosylation recognition sites). This ORF D N A is cloned from the HindlII-D fragment and is capable of hybrid-selecting mRNA with a 100 kda translational product. 072-87 Recombinant hepatitis B virus gene expression in Vero cell culture
Kitasato Res. Inst. Jpn. 1282 078; 12 December 1986 Two hepatitis B virus (HBV) gene-derived Ba,nHI fragments are linked in series and inserted into a plasmid vector capable of replication in Escherichia coil and in animal cells. The recombinant plasmid can be introduced into Vero cells and the transformed Vero cells can be incubated in a medium to yield HBV protein having the same biological, physical and chemical properties as human serum-derived HBV protein. A typical plasmid vector is pSVNH2 in which two HBV D N A fragments have been inserted in series. The vector is 11.0 kb, and contains 2.3 kb of plasmid pBR322, 342 bp of SV40 origin of replication, 1.845 kb of the neomycin-resistance gene from the E. coli plasmid pKC7, and two linked HBV fragments (3.2 kb, containing the pre-S gene). Plasmid pSVNH2 is introduced into Vero cells for production of HBV surface antigen, pre-S added surface antigen and HBe antigen. Expression of the antigen genes is stable even after subculture of the Vero cells. E. coil KMB3306 carrying plasmid pSVNH2 has been deposited as FERM P-8200. 073-87 Cell membrane proteins obtained from T lymphocytes; methods for their production and compositions containing them useful for autoimmune disease treatment Yeda Res. Develop. US 4634 590; 6 January 1987 Compositions for the prevention and treatment of autoimmune diseases are described which comprise as an active ingredient membrane material shed from autoimmune T lymphocytes or T lymphocytes activated by a pressure application and release process. The invention relates to e.g. vaccines produced using the proteins. The T lymphocytes are subjected to a high hydrostatic pressure which is gradually released to give an effective shedding of membrane material which retains a high degree of biological activity. The pressure applied is e.g. 500-1500 arm, and the pressure is built up over 5 min, maintained at the upper level for 10-45 min, then released over 5-15 rain. The proteins obtained are used for the prevention and treatment of autoimmune diseases. 074-87 Protective synthetic peptide against malaria used for producing antibodies against Plasmodium vivax
US Dept. Health Human Serv. US 6799 464; 23 September 1986 A synthetic peptide capable of inducing antibodies protective against human malarial infection and the cloning of the gene encoding the peptide are new. The amino acid and nucleotide sequences of the peptide and the gene are specified. The peptide has at least in part the amino acid sequence Gly-AspAla-Asp-Gly-Gln-Pro-Ala. The cloned gene capable of directing the synthesis of the peptide in a suitable genomic medium has at least in part the nucleotide sequence CCAG A C - A G A - G C A - G A T - G G A - C A G - C C A - G C A . The peptide is used for inducing immunization against malaria. 075-87 Vaccine for protection against Streptococcus equi containing avirulent mutant obtained from parent strain by mutagenesis
Cornell Res. Found. World 8700 436; 29 January 1987 A vaccine for protecting horses against Streptococcus equi (causing the disease strangles) comprises an avirulent strain of S. equi which stimulates an antibody response in the nasopharyngeal mucosa. The new strain is made by mutation of a virulent strain and retains a protein providing an Mprotein fragment of mol. wt 41 000. This fragment stimulates formation of IgG and IgA antibodies similar to those found in animals which have recovered from infection with virulent S. equi. The avirulent strain is non-encapsulated, and is especially S. equi 709-27 (ATCC 53186). The vaccine may be given intranasally or orally. 709-27 is developed from the highly virulent strain CF32 (ATCC 53185) by nitrosoguanidine mutagenesis followed by screening for loss of virulence and for ability to protect mice. The vaccine provides efficient protection without any side-effects in adult animals. 076-87 Variant cell culture line huGK-14 originating in human liver cancer useful in the production of large amounts of hepatitis B virus surface antigen for vaccine
Gan Kenkyu Kai Jpn. 1268 177; 27 November 1986 A human variant cell culture, line huGK-14, is described which can be used in the production of large quantities of hepatitis B virus surface antigen (I) for use in vaccines. This cell line originated in a human liver cancer and contains a gene encoding (I) incorporated in eight places/chromosome paproide. The cell culture can be grown in an inexpensive culture medium at 36.5 + / - 1°C. Hyperplasia is suitable for cell adding 10% serum to DM-160 basal medium. Good division hyperplasia is recognized in serum-free Williams E basal medium. Production of (I) increases on addition of dexamesazon to the culture medium. 077-87 Coccidiosis vaccine comprising extract ofEimeria teneUa sporulated oocyst
Merck USA US 4639 372; 27 January 1987 Extracts from the sporulated oocyst and sporozoite stages of Eimeria tenella have been prepared and used to immunize chickens. Post-grind supernatant fluid is obtained from sporulated oocysts after grinding this stage and collecting the supernatant by centrifugation. Sporozoites are obtained by subjecting the pelleted parasite materials, derived from sporulated oocysts after grinding and centrifugation, to an existing solution, then centrifugation and anion exchange column chromatography. The products contain immunogenic polypeptides of 235, 105, 94, 82, 68, 45, 40, 26 and 23 kDa. In addition polypeptides of less than 10, 10, 15, 19, 50 and 330 kDa are immunogenic and react with monoclonal antibodies specific to E. tenella extract. One or more of these polypeptides may be used as an antigen to protect against coccidiosis. 078-87 Vaccine, Vol. 5, September 1987 251
Merck USA Eur. 210 931; 4 January 1987 A 2.6 kb fragment of varicella zoster virus (VZV) D N A having a specified D N A sequence is new. The polypeptide encoded by the D N A and having a specified amino acid sequence is also new. The polypeptide can be used as a vaccine to protect against VZV disease. The antigens can also be used diagnostically to measure VZV titres. Plasmids from a VZV genomic library are used to hybrid-select R N A from VZV-infected cells. In vitro translational products are immunoprecipitated by guinea pig antibodies raised to gB glycoprotein purified by monoclonal antibody affinity chromatography. It is found that a 100kDa polypeptide is immunoprecipitated from m R N A selected by the HindllI-D fragment. DNA sequence analysis of this region of the VZV genome reveals a 2.6 kb open reading frame (ORF) which could encode a 100 kDa protein with a glycoprotein-like structure (hydrophobic leader, hydrophobic anchor, 9-N-glycosylation recognition sites). This ORF D N A is cloned from the HindlII-D fragment and is capable of hybrid-selecting mRNA with a 100 kda translational product. 072-87 Recombinant hepatitis B virus gene expression in Vero cell culture
Kitasato Res. Inst. Jpn. 1282 078; 12 December 1986 Two hepatitis B virus (HBV) gene-derived Ba,nHI fragments are linked in series and inserted into a plasmid vector capable of replication in Escherichia coil and in animal cells. The recombinant plasmid can be introduced into Vero cells and the transformed Vero cells can be incubated in a medium to yield HBV protein having the same biological, physical and chemical properties as human serum-derived HBV protein. A typical plasmid vector is pSVNH2 in which two HBV D N A fragments have been inserted in series. The vector is 11.0 kb, and contains 2.3 kb of plasmid pBR322, 342 bp of SV40 origin of replication, 1.845 kb of the neomycin-resistance gene from the E. coli plasmid pKC7, and two linked HBV fragments (3.2 kb, containing the pre-S gene). Plasmid pSVNH2 is introduced into Vero cells for production of HBV surface antigen, pre-S added surface antigen and HBe antigen. Expression of the antigen genes is stable even after subculture of the Vero cells. E. coil KMB3306 carrying plasmid pSVNH2 has been deposited as FERM P-8200. 073-87 Cell membrane proteins obtained from T lymphocytes; methods for their production and compositions containing them useful for autoimmune disease treatment Yeda Res. Develop. US 4634 590; 6 January 1987 Compositions for the prevention and treatment of autoimmune diseases are described which comprise as an active ingredient membrane material shed from autoimmune T lymphocytes or T lymphocytes activated by a pressure application and release process. The invention relates to e.g. vaccines produced using the proteins. The T lymphocytes are subjected to a high hydrostatic pressure which is gradually released to give an effective shedding of membrane material which retains a high degree of biological activity. The pressure applied is e.g. 500-1500 arm, and the pressure is built up over 5 min, maintained at the upper level for 10-45 min, then released over 5-15 rain. The proteins obtained are used for the prevention and treatment of autoimmune diseases. 074-87 Protective synthetic peptide against malaria used for producing antibodies against Plasmodium vivax
US Dept. Health Human Serv. US 6799 464; 23 September 1986 A synthetic peptide capable of inducing antibodies protective against human malarial infection and the cloning of the gene encoding the peptide are new. The amino acid and nucleotide sequences of the peptide and the gene are specified. The peptide has at least in part the amino acid sequence Gly-AspAla-Asp-Gly-Gln-Pro-Ala. The cloned gene capable of directing the synthesis of the peptide in a suitable genomic medium has at least in part the nucleotide sequence CCAG A C - A G A - G C A - G A T - G G A - C A G - C C A - G C A . The peptide is used for inducing immunization against malaria. 075-87 Vaccine for protection against Streptococcus equi containing avirulent mutant obtained from parent strain by mutagenesis
Cornell Res. Found. World 8700 436; 29 January 1987 A vaccine for protecting horses against Streptococcus equi (causing the disease strangles) comprises an avirulent strain of S. equi which stimulates an antibody response in the nasopharyngeal mucosa. The new strain is made by mutation of a virulent strain and retains a protein providing an Mprotein fragment of mol. wt 41 000. This fragment stimulates formation of IgG and IgA antibodies similar to those found in animals which have recovered from infection with virulent S. equi. The avirulent strain is non-encapsulated, and is especially S. equi 709-27 (ATCC 53186). The vaccine may be given intranasally or orally. 709-27 is developed from the highly virulent strain CF32 (ATCC 53185) by nitrosoguanidine mutagenesis followed by screening for loss of virulence and for ability to protect mice. The vaccine provides efficient protection without any side-effects in adult animals. 076-87 Variant cell culture line huGK-14 originating in human liver cancer useful in the production of large amounts of hepatitis B virus surface antigen for vaccine
Gan Kenkyu Kai Jpn. 1268 177; 27 November 1986 A human variant cell culture, line huGK-14, is described which can be used in the production of large quantities of hepatitis B virus surface antigen (I) for use in vaccines. This cell line originated in a human liver cancer and contains a gene encoding (I) incorporated in eight places/chromosome paproide. The cell culture can be grown in an inexpensive culture medium at 36.5 + / - 1°C. Hyperplasia is suitable for cell adding 10% serum to DM-160 basal medium. Good division hyperplasia is recognized in serum-free Williams E basal medium. Production of (I) increases on addition of dexamesazon to the culture medium. 077-87 Coccidiosis vaccine comprising extract ofEimeria teneUa sporulated oocyst
Merck USA US 4639 372; 27 January 1987 Extracts from the sporulated oocyst and sporozoite stages of Eimeria tenella have been prepared and used to immunize chickens. Post-grind supernatant fluid is obtained from sporulated oocysts after grinding this stage and collecting the supernatant by centrifugation. Sporozoites are obtained by subjecting the pelleted parasite materials, derived from sporulated oocysts after grinding and centrifugation, to an existing solution, then centrifugation and anion exchange column chromatography. The products contain immunogenic polypeptides of 235, 105, 94, 82, 68, 45, 40, 26 and 23 kDa. In addition polypeptides of less than 10, 10, 15, 19, 50 and 330 kDa are immunogenic and react with monoclonal antibodies specific to E. tenella extract. One or more of these polypeptides may be used as an antigen to protect against coccidiosis. 078-87 Vaccine, Vol. 5, September 1987 251